U.S., July 3 -- ClinicalTrials.gov registry received information related to the study (NCT07681388) titled 'CD19 CAR-T Therapy for Refractory Pemphigus Vulgaris' on June 19.
Brief Summary: This is an investigator-initiated, single-center, single-arm, open-label exploratory clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of autologous CD19 CAR-T cell therapy in patients with refractory pemphigus vulgaris.
Study Start Date: Jan. 15
Study Type: INTERVENTIONAL
Condition:
Pemphigus Vulgaris
Intervention:
BIOLOGICAL: Autologous CD19 CAR-T cells
Autologous CD19 CAR-T cells are manufactured ex vivo using the participant's own T cells collected by leukapheresis. The CAR construct targets CD19-expressing...